Photonis Scientific, Inc.
Visit Photonis at booth #407 during the 71st ASMS Conference
STURBRIDGE, MA / ACCESSWIRE / May 23, 2023 / Photonis has announced that the company will be exhibiting at the 71st American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, taking place June 4 - June 8, 2023, at the George R. Brown Convention Center in Houston, TX.
Photonis can be found at booth 407 in the exhibitor hall. Attendees are encouraged to meet and speak to the company's diverse team of technical experts and learn more about how their industry-leading MS Detection Technology will benefit new applications in Mass Spectrometry due to unprecedented performance levels.
At this occasion, Photonis, the leaders in Time-of-Flight (TOF) detection technologies, will showcase their latest advancements in TOF detection with additions to their existing detector platforms - the APTOF and BPTOF Series.
Photonis presents the APTOF A300, a capacitively-coupled, compact assembly detector designed for small footprint and/or benchtop TOF systems. The APTOF A300 integral AC-coupled high voltage isolation prevents damage to the digitizer and provides MS Instrument manufacturers with significant cost savings.
In parallel, the company will introduce the BPTOF B380, an optically coupled Bi-Polar TOF detector with never-before-seen lifetime benefits, based on a patented technology from Photonis.
Ulrich Laupper, President and General Manager of Photonis' Ultimate Detection Business Unit:
"We are excited to introduce the next generation of Time-of-Flight detection technology at this year's ASMS Conference. Photonis is committed to extensive investments into Research and Development activities in order to provide our industry partners market-leading detector solutions. The APTOF A300 and BPTOF B380 provide mass spectrometry instrument manufacturers an unmatched cost-of-ownership value proposition. In addition, it also enables them to offer new advanced applications to their end users. We are very proud to be part of the ASMS community and contribute to advance science and quality of life with our technologies."
Photonis' Time-of-Flight detectors support some of the world's most sensitive TOF-MS applications. Their patented technologies and distinct Microchannel Plates ensure optimum temporal resolution, excellent mass sensitivity, unmatched lifetime and superb dynamic range; enabling mass spectrometers to be optimized with the best detector on the market, no matter the analysis requirements. Photonis specializes in working in partnership with TOF-MS Instrument designers to understand the requirements needed in each instrument to provide the longest-lasting, accurate detectors specifically designed for each instrument.
About Photonis
Photonis is a market-leading provider of technologies used in the detection and amplification of photons, ions, electrons, and neutrons. We innovate and engineer the highest quality technology solutions for integration into a wide variety of applications, such as mass spectrometry, night vision optics, digital cameras, nuclear instrumentation, life-science and physics research, space exploration, and many others. With over 80 years of experience in partnering with our customers to provide the world's leading detection systems, Photonis has the experience to meet the specific challenges of the many markets we serve.
For more information, please contact us or visit us at booth #407 during the conference.
Contact Information
Nicole Poirier
Marketing Manager
n.poirier@usa.photonis.com
SOURCE: Photonis
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/756322/Photonis-Expands-Market-Leading-Mass-Spectrometry-Detection-Technology
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
eComplete Partners with Sourceful to build AI-Native Creative Operations Across Portfolio18.11.2025 15:00:00 CET | Press release
MANCHESTER, UK / ACCESS Newswire / November 18, 2025 / eComplete, the private equity firm behind Current Body's £300 million London Stock Exchange listing, has announced a strategic partnership with Sourceful, the Manchester-based technology company whose Riverflow 1 model ranks as the world's leading AI image editing model. The partnership brings Sourceful's AI-native creative platform to eComplete's portfolio of direct-to-consumer brands, enabling them to generate brand-accurate, production-ready creative assets at scale across e-commerce, social, marketplace and retail. This makes eComplete the first major private equity investor to adopt AI-native creative infrastructure as a core operational advantage. Why this matters Every consumer brand today faces the same constraint: producing thousands of creative assets, product images, ads, videos, packaging, that feel authentically on-brand across every channel and market. This challenge has intensified dramatically over the past three ye
IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release
Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres
General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release
DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom